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ABSTRACT 
Rheumatoid arthritis (RA) is a disabling chronic autoimmune disease characterized by 
joint pain, and potentially leading to a serious decay of life quality. Pain remains the most 
important problem for patients with RA, and there is an obvious need to increase the 
knowledge of pain patterns in early disease and relation to anti-rheumatic treatment. The first 
three papers of this thesis are based on the population-based early RA cohort (EIRA study), 
linked to the Swedish Rheumatology Register (SRQ). The main focus was to investigate pain 
patterns in early RA and the relation to other clinical factors. First we studied the frequency 
of remaining pain after three months’ treatment with the first-line agent methotrexate, and 
found this outcome in a majority of the patients. Moreover, remaining pain was found in 
almost a third of patients with good clinical response, and predicted by high disability and 
low inflammatory activity at diagnosis. Further, we found that remaining pain despite 
satisfactory inflammation control one year after diagnosis, strongly predicts development of 
widespread pain and fatigue three years after diagnosis. Next, we used a more severe pain 
outcome, unacceptable pain, and studied the pain course during the first five years after 
diagnosis. We found that almost a third of the patients still have unacceptable pain after one 
year of adequate anti-rheumatic treatment, and there is minor further decrease of the 
proportion with this outcome after five years, suggesting that optimization of immune 
suppressive treatment can not decrease pain levels further at this stage. Women were more 
likely than men to develop unacceptable pain and the strongest predictors at diagnosis for this 
outcome were disability, patients global assessment (PGA) of disease, high number of tender 
joint count (TJC) and low number of swollen joint count (SJC). At diagnosis, pain correlated 
to disease activity and SJC/TJC, and this correlation increased after three months to stable 
levels that remained throughout the first five years of disease. TJC was higher correlated to 
pain than SJC during the whole early RA disease course.  Pain mechanisms are closely linked 
to the autonomic nervous system (ANS), and dysfunction of autonomic activity is well 
documented in pain conditions such as fibromyalgia (FM). Our investigation of ANS 
function in RA and FM revealed different autonomic patterns that could also be coupled to 
differences in neuroinflammation. Thus, central nervous system (CNS) mechanisms in RA 
were characterized by an IL-1β dominated intrathecal immune activation, which, unlike in 
FM, was coupled to reduced parasympathetic activity. These data indicate an earlier unknown 
interaction between CNS mediators and autonomic activity, which may be of interest to 
further identify treatment targets in neuro-immune regulation. Conversely in FM, there was 
an increase of central IL-8, known to associate with pain regulation, and FM also displayed 
an upregulation of sympathetic activity, which was independent of neuroinflammation.  
Altogether, our data imply that remaining pain after anti-rheumatic treatment is not 
uncommon. The frequency of remaining pain stabilizes during the first years of disease and is 
a strong risk factor for subsequent generalized pain. Furthermore, we have shown that 
neuroinflammatory patterns in RA are coupled to autonomic dysfunction, and also clearly 
differ from FM, indicating different mechanisms behind RA pain and dysfunctional pain. The 
findings of this thesis have illustrated the pain problem in early RA, and hopefully this 
knowledge may contribute to early identification and treatment of patients at risk of 
developing pain conditions in connection to their rheumatic disease. 
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1 INTRODUCTION  
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints where pain is a 
general and important symptom  Pain is often the earliest symptom bringing the patient to 
rheumatology care for the first time and is highly ranked by patients. The recent decade, anti-
rheumatic treatment strategies have improved and the aiming for remission has led to better 
treatment results and less functional impairment in many patients. However, still it is a 
clinical fact that many patients continue to have pain, sometimes also when the inflammation 
has been adequately suppressed. The overall aim of this thesis is to investigate the extent of 
the pain problem in RA, and how this may relate to other clinical factors at diagnosis. 
Moreover, the mechanisms of pain and fatigue in relation to inflammation and autonomic 
activity have been studied. A future goal would be to identify patients at risk of developing 
long-standing pain, and provide efficient preventing strategies in the early phase of the 
disease.  
1.1 RHEUMATOID ARTHRITIS 
1.1.1 Clinical course and epidemiology 
Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by pain, 
swelling, and stiffness of the joints, subsequently leading to joint destruction, functional 
impairment and chronic pain [1]  The overall prevalence of RA is 0.5-1% and an incidence of 
50 per 100.000 in Sweden [2, 3]. The disease is more common in women, and the female to 
male ratio is 3:1. RA affects all age groups, with highest incidence between 45 and 65 years 
[4, 5].  
1.1.2 Etiology  
The etiology of RA remains unclear, although an interaction between autoimmune 
mechanisms and environmental exposures have been implicated as important for the 
pathogenesis [6, 7]. Thus, the concordance of RA is about 15% for homozygotic twins [8, 9] 
suggesting that environmental factors in addition to the genetic influence may have an 
important role for development of the disease. Specific HLA alleles (e.g. HLA-DRB1) are 
among the strongest genetic risk factors for RA, affecting both disease susceptibility and 
disease severity [10]. Several HLA-DRB1 alleles, for example *01:01 and *04:01 share a 
specific amino acid sequence (the shared epitope (SE); position 70-74 in the third region of 
the DRB1 beta chain) and this sequence is located in the peptide-binding groove of the 
protein. Other important risk genes for RA include PTPN22 and CTLA-4 [11, 12].. 
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Furthermore, HLA-DRB1*4 strongly associated with presence of anti-CCP antibody 
positivity patients with RA and may predict more progressive disease [13]  while there is no 
association with RF positivity [14]  Among the environmental risk factors, smoking is the most 
important [15] , and has been found to interact with genetic susceptibility [16]. Other 
environmental risk factors include breast-feeding, adverse pregnancy outcome, previous 
blood transfusion and obesity [17].  
1.1.3 Autoantibodies in RA 
In 1940 rheumatoid factor (RF) was discovered [18, 19] and for many years was used as a 
marker of disease severity in RA. The later findings of autoantibodies to citrullinated 
peptides, i.e. anti-citrulline peptide antibodies (ACPA), with a high specificity (96-98%) for 
RA was a major step forward, both in clinical diagnosis and further understanding of RA 
pathogenesis [20] . Interestingly, ACPA have also been found in the circulation before disease 
onset [21], and suggested to play a role in the initiation of the disease [16] as well as osteoclast 
activation/bone destruction [22, 23]  and pain mechanisms [24] . 
1.1.4 Treatment considerations 
The current pharmacological treatment of RA include nonsteroidal anti-inflammatory drugs 
(NSAIDs), disease modifying anti-rheumatic drugs (DMARDs), biologics and corticosteroids 
[25]. Whereas NSAIDs often provide pain relief in the short-term, DMARDs also have the 
effects to retard or prevent joint destruction.  Methotrexate is considered the first-line 
DMARD agent in RA and has proven efficacious to induce remission in about a third of the 
patients [26, 27]. During the last decade, the treatment goals in RA have switched from a focus 
on low disease activity into reaching total inflammatory remission [28]. The use of biologics in 
disease management has improved disease outcome and may further suppress disease activity 
and prevent joint destruction in patients with unsufficient clinical response to methotrexate. 
Biologic agents registered in Sweden include tumor necrosis factor (TNF) antagonists, 
abatacept (inhibition of the T-cell co-stimulation), tocilizumab (IL-6 receptor inhibition), 
rituximab (B-cell depletion) and anakinra (IL-1beta receptor antagonist). [29] . Corticosteroids 
provide important adjunct therapy in the management of arthritis, and addition of low-dose 
steroids to DMARDs is recommended in moderately active early RA [25] . Moreover, intra-
articular injections of steroids may be efficacious for suppressing arthritis in single joints. 
Further, non‐pharmaceutical interventions are important, where physical exercise is a 
hallmark in the management of RA. Moreover, team work between  rheumatologists, 
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physiotherapists, occupational therapists, social worker and rheumatology nurses provide 
important management of the newly diagnosed RA patient[30-32]  
1.1.5 Clinical features and classification criteria 
In the majority of RA patients, the onset of the disease is insidious, with joint pain, stiffness 
and symmetrical swelling of a number of peripheral joints (figure 1). Initially, pain may be 
experienced only on movement of joints, but subsequently also pain at rest and prolonged 
early morning stiffness develops [33]. If left untreated, various degrees of joint destruction, 
deformity, and a significant decline in functional status which can affect the patient’s capacity 
to perform the activities of daily living [34]. In addition to articular deterioration, constitutional 
symptoms such as fatigue, malaise, weight loss, and low-grade fever, may be present. Less 
often, extra articular organ involvement such as the skin, heart, lungs, and eyes can also be 
significant [35, 36]. 
Figure 1. Symmetric swelling (arthritis) of small joints in RA. 
 
 
RA is primarily a clinical diagnosis. No single diagnostic test definitively confirms the 
diagnosis. However, several tests can provide objective data that increase diagnostic certainty 
and allow disease progression to be followed [37]. In 1987, the American College of 
Rheumatology (ACR) established classification criteria for rheumatoid arthritis [38] (Table 1), 
originally designated for research and clinical trial purposes. Despite that intent, the criteria 
have been widely used to make the diagnosis of RA.  
Table 1. The 1987 revised classification criteria for rheumatoid arthritis [38] 
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Rheumatoid arthritis is defined by the presence of 4 or more of the following criteria: 
 
1. Morning stiffness in and around joints lasting at least 1 hour before maximal improvement 
 
2. Soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician 
 
3. Swelling (arthritis) of the proximal inter phalangeal metacarpophalangeal, or wrist joints  
 
4. Symmetric swelling (arthritis) 
 
5. Rheumatoid nodules 
 
6. The presence of rheumatoid factor 
 
7. Radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints. 
 
 
Criteria 1-4 must have been present for at least 6 weeks 
 
In order to be able to identify possible rheumatoid arthritis earlier, and prevent delay of 
diagnosis, new RA classification criteria were formed 2010 by the ACR and the European 
League Against Rheumatism (EULAR) [39] (Table 2). 
Table 2. The 2010 ACR/EULAR classification criteria of rheumatoid arthritis [39] 
Target population: patients who (1) have at least 1 joint with clinical synovitis and (2) 
with synovitis not better explained by other disease.                             
Joint involvement (tender/swollen) 
1 large joint                                                                                                                                        
2-10 large joints                                                                              
1-3 small joints (± involvement of  large joints)                             
4-10 small joints (± involvement of  large joints)                           
>10 joints (at least 1 small joint)                                                     
 
0
1 
2 
3 
5 
Serology 
Negative RF & ACPA                                                                     
Low-positive RF/low positive ACPA                                             
High-positive RF/high-positive ACPA                                           
 
0 
2 
3 
Acute-phase reactant 
Normal CRP & ESR                                                                        
Abnormal CRP & ESR                                                                    
 
0 
1 
Duration of symptoms  
< 6 weeks                                                                                          
≥ 6 weeks                                                                                          
 
0 
1 
Add score of categories A-D: ≥ 6/10 = define RA 
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1.1.6 Disease activity and clinical response to treatment  
There has been a dramatic improvement in the treatment of RA in the last 2 decades and 
disease remission is today considered to be a realistic goal for patients and physicians [40]. 
Disease activity is measured using a standardized index, the DAS28. DAS28 is a validated 
index of RA disease activity [41] and calculated using the results of the 28 tender joint count 
(TJC 28) and the 28 swollen joint count (SJC 28), erythrocyte sedimentation rate (ESR) and 
patient global assessment (PGA) (Table 3). The level of disease activity and the cut-off points 
measurement is classified as low (DAS28≤3.2), moderate (3.2<DAS28≤5.1), or high 
(DAS28>5.1), cut-off point of DAS28 <2.6 is considered as clinical remission (Table 4) [42]. 
 
Table 3. Disease activity index                       
DAS28 index Scoring scale 
TJC 0 - 28 
SJC 0 - 28 
ESR 0 -140 
PGA 0 -100 
 
Table 4. Disease activity cut-off measures 
 
For the assessment of the efficacy and response to the anti-rheumatic treatment, changes in 
the disease activity score 28 (DAS28) is measured by criteria established by the European 
League Against Rheumatism (EULAR)[43]. According to these criteria, good EULAR 
response is defined as a decrease in DAS28 of >1.2 and an attained DAS28 of ⩽3.2. No 
EULAR response is defined as a decrease in DAS28 of ⩽0.6 with an attained DAS28 of 
>5.1. Patients not fulfilling these criteria are classified as moderate EULAR responders 
(Table 5) [44]. 
 
Level of disease activity DAS28 score 
Remission  < 2.6 
Low  ≤ 3.2 
Moderate  > 3.2 and ≤5.1 
High  >5.1 
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Table 5. European League Against Rheumatism (EULAR) response criteria in RA. 
 
1.2 PAIN PERCEPTION  
1.2.1 Definition of pain 
There are several descriptions of the pain experience, and one often described is the pain 
definition from IASP: “Pain is an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage” . Pain can 
range from localized, such as joint pain due to synovial inflammation, or it can be more 
diffuse as in disorders like fibromyalgia. In general, pain is the most common reason that 
individuals seek medical attention and it has been considered as the “fifth vital sign” [45]  
1.2.2 Classifications of pain 
Mechanism-based pain diagnosis can be difficult, However, classifying pain could be 
helpful to the physicians for guiding assessment and treatment. The two most frequently 
used approaches for classifying pain are based on pain duration i.e. acute vs chronic pain 
(usually pain more than three months) and underlying pathophysiology i.e. nociceptive vs. 
neuropathic pain. Moreover, pain with no clear underlying somatic cause as well presence 
of psychological factors is classified as psychogenic pain. Absence of an identifiable 
physical or psychologic cause, pain is classified as idiopathic pain [46].  
1.2.3 Nociceptive pain 
The type of pain that is caused by normal response to noxious insult or injury of tissues, 
could be somatic such as skin, musculoskeletal and joint pain and is often well localized, or 
visceral such as organs and smooth muscles, often referral.  
EULAR  
Response 
 
Improvement of DAS28  
from baseline 
Good  >1.2 
Moderate  >0.6 and ≤1.2 
None  ≤0.6 
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Nociceptive pain usually described as a sharp, aching or throbbing pain through activation of 
nociceptors — specialized sensory neurons that are stimulated by noxious mechanical, 
thermal or chemical stimuli [47]. Nociceptors transform these stimuli into electrical signals and 
relay them to the central nervous system. Nociceptive pain tends to be short-lived, but if it 
persists beyond 12 weeks, it becomes chronic pain.  
The link between the nervous and immune systems is important in the mechanism of 
transition from acute to chronic pain. The pro-nociceptive influence on peripheral nerve 
fibers is mediated by locally released cytokines by variety of cells such as macrophages, 
fibroblast and mast cells. However, these peripheral cytokines do not easily cross the blood–
brain barrier. Moreover, the central nervous system has its own source of cytokines produced 
by glia cells that matters in pain processing [48]  
The main peripheral mechanism underlying acute nociceptive pain is a change in the activity 
of the nociceptors located in the tissue which makes them more sensitive to normally painful 
stimuli (hyperalgesia) or normally non-painful stimuli (allodynia) [49]. However, in chronic 
pain, central nervous system sensitization and facilitation of nociceptive stimuli, cause a 
generalized reduction in the pain threshold leading to the appearance of hyperalgesia and 
allodynia [50], 
Involvement of cytokines in nociceptive hypersensitivity has previously been suggested. 
There is evidence that pro-inflammatory cytokines IL-1β, IL-8 and TNF contribute to pain 
and hyperalgesia by different mechanisms [51]. 
1.2.4 Neuropathic pain  
Neuropathic pain is caused by a primary lesion or disease in the somatosensory nervous 
system. Neuropathic pain is often described as sharp, stabbing or shooting. Some possible 
reasons for neuropathic pain include nerve irritation, nerve damage or the formation of a 
neuroma.[52] 
1.2.5 Psychogenic pain 
Type of pain caused by a psychological disorder, such as depression or anxiety and it may 
have physical complications, such as fatigue and muscle aches and pain. Non-
pharmaceutical pain treatments, combined with antidepressants or other psychological 
medications, are often more effective than traditional painkillers.  
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1.2.6 Idiopathic pain  
Idiopathic pain exists when there is no known physical or psychological cause. Idiopathic 
pain is more common in people who have a pre-existing pain disorder. These disorders 
include temporomandibular joint (TMJ) disorders and fibromyalgia. Because its cause is 
not apparent, idiopathic pain is often difficult to treat. 
1.3 PAIN IN RA 
Pain is the most common symptom of patients with rheumatic disorders in general, and also a 
major burden of RA [53]. In spite of effective immune-suppressive therapies, observational 
studies show that a large number of patients with RA have remaining pain affecting quality of 
life. This was seen in an international observational study, where the majority of the studied  
patient cohorts with established RA in Europe (60%) and USA (65%) reported discontent 
with pain management [54]. the intensity of pain is only weakly correlated with measures of 
peripheral inflammation [55] 
Pain may cause severe suffering in the individual RA patient and also contribute to functional 
impairment. The peripheral nociceptive mechanisms of arthritis involve direct action of 
several inflammatory mediators, such as prostaglandins, bradykinins and neuropeptides [56, 57]. 
In addition, pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin 
IL-1β, IL-6 and IL-17 have all been shown to sensitize peripheral neurons in experimental 
arthritis [58]. These mechanisms lead to lower thresholds for mechanical pain in the joint. 
Moreover, during joint inflammation, afferent neurons in connection to the joint are 
sensitized. Low threshold nociceptive mechanoreceptors with thick and thin myelinated 
axons (Aβ and Aδ fibers) show enhanced responses to pressure onto the joint and movements 
of the joint. Importantly, numerous high-threshold units, defined as nociceptors by their high 
mechanical threshold, become sensitized and start to respond to light pressure and 
movements in the working range of the joint. Most of these units are thin myelinated (Aδ 
fibers) or unmyelinated (C fibers). Finally, initially mechano-insensitive fibers (silent 
nociceptors) become responsive to mechanical stimulation of the joint and contribute to the 
afferent inflow into the spinal cord during inflammation. Collectively, these changes provide 
the afferent sensory basis of joint pain The consequence of these processes is that under 
inflammatory conditions the nociceptive system is activated by normally innocuous and no 
painful mechanical stimuli. 
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On a group level, RA patients have increased pain sensitivity in RA compared to controls [50] 
and this also increase with disease duration, suggesting dynamics of the pain regulation of the 
disease. Apart from peripheral effects, earlier data have also depicted central nervous impact 
on pain modulation in arthritis, and TNF and IL-6 may have important effects in this context 
[59]. Clinically, this is further underscored by the high co-morbidity between RA and 
generalised pain syndromes such as fibromyalgia and chronic widespread pain (FM) [60, 61]. In 
conclusion, RA is associated with an increased pain sensitivity on the basis of both peripheral 
and central pain sensitization. 
1.4 CHRONIC WIDESPREAD PAIN AND FIBROMYALGIA  
Fibromyalgia (FM) is a non-inflammatory non-articular rheumatic condition characterized by 
chronic widespread musculoskeletal pain and generalized tiredness as well as sleep disorders 
and cognitive dysfunction [62]. According to classification criteria of the American College of 
Rheumatology 1990, fibromyalgia is defined as the following: History of widespread pain 
that has been present for at least three months, as well as pain in at least 11 of 18 tender point 
sites on digital palpation (figure 2 and table 6) [63] Digital palpation should be performed 
with an approximate force of 4 kg. A tender point has to be painful at palpation, not just 
"tender."  
 
 
                                                                        
 
 
 
 
 
 
 
 
Figure 2. Tender points in fibromyalgia 
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Table 6. ACR 1990 criteria for Fibromyalgia [63] 
 
1- History of  widespread pain for at least 3 months 
Pain is considered widespread when all of the following are present:  
- Pain in the left side of the body,pain in the right side of the body 
- Pain above the waist 
- Pain below the waist 
- Axial skelital pain (cervical spine or anterior chest or thoracic spine or low back) 
 
2- Pain in 11 of 18 tender points sites on digital palpitation  
Tender paoint sites: 
- Bilateral, at the suboccipital muscle insertion 
- Bilateral, at the anteriar aspects of the intertrasverse space at C5-C7 
- Bilateral, at the midpoint of the upper Trapezius border 
- Bilateral, at Suoraspinatus, above the scapula spine’’ 
- Bilateral, at the second costocondral junctions 
- Bilateral, 2 cm distal to the lateral epicondyles’ 
- Bilateral, in the upper outer quadrants of the Gluteus muscles 
- Bilateral, posterior to the greater Trochanter 
- Bilateral, at the medial fat proximal to the Knee joint 
The prevalence of FM in the general global population is 2–7%, and the disease mainly 
affects women (80%) [62]. FM is often associated with depression and decreased quality of life 
as well as decreased work capacity [64, 65]. Patients with both FM and depression have a more 
decreased quality of life and reduced ability to focus attention compared with patients with 
FM only [66] . The mechanisms of pain in FM has not been fully elucidated, but several 
studies have reported dysfunction in both the peripheral and central nervous system. 
Moreover, normal muscle work upregulate sensitivity in pain receptors in the muscle leading 
to repeated release of nociceptive and inflammatory substances causing long-lasting 
peripheral and central sensitization. [67, 68]. 
Recently, there has been focus on activation of glia cells (astrocytes and microglia)  as a 
potential mechanism in dysfunction of pain regulation in the CNS leading to chronic pain [69] 
[70] Moreover, in patients with fibromyalgia, elevated cerebrospinal fluid and serum 
concentrations of IL-8 has earlier been reported [71],  
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Chronic widespread pain is also common in RA, and the prevalence of FM in RA patients 
may be as high as 10–20%  [60]. When a patient has both RA and FM, determining the degree 
of RA activity may be difficult, because these patients typically have higher scores for pain 
and disability [55]. RA patient with concomitant FM have significantly higher DAS28 score 
than patients without FM [72] which is likely due to higher perception of pain in the former 
group [73]. There are a number of factors influencing pain and pain experience, including age, 
gender, culture,  depression, anxiety and stress [74, 75]. All these factors are of great importance 
in the overall experience of pain and the interrelationship of these is often referred to as the 
biopsychosocial model of pain  [76] (figure 3) 
 
Figure 3. The biopsychosocial model of factors influencing pain  
1.5 FATIGUE IN RA 
Fatigue can be defined as an overwhelming sense of tiredness, lack of energy and feeling of 
exhaustion. Women are more likely to feel fatigued than men [77]. Pathological fatigue does 
not improve with rest and is a complication of several acute and chronic inflammatory 
diseases, including arthritis [78]. Fatigue can be a severe and distressing phenomenon to the 
patient and interfere with the patient's life, including work disability and lower quality of life 
as well fatigue interferes with emotional, physical and social functions.  
Fatigue is a common complaint among patients with RA and is regarded as an extra-articular 
symptom of the disease [79]. More than 80% of RA patients have experienced fatigue [80] and 
over a half of the patients have reported fatigue as the most problematic symptom [81]. Fatigue 
in RA is strongly associated with poor sleep, functional disability, pain, depressive symptoms 
and cause substantial distress and reduced work capacity [81, 82]. Moreover, systemic 
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inflammation has been shown to associate with activation of immunological mechanisms in 
the brain, where a role in the processes contributing to fatigue have been suggested. Thus, 
intrathecal injection of IL-1β in rodents leads to sickness behavior and fatigue, respectively 
[83, 84]. Moreover, activation of the IL-1 system in RA CNS has been coupled to increased 
fatigue [85] . Furthermore, in another study, daily administration with IL-1R antagonist 
significantly reduce fatigue in RA patients [86]. The hypothesis of underlying inflammatory 
mechanisms behind fatigue is further underscored by fatigue-suppressing effects of TNF-
blockade [87]. 
Related to its multifactorial features, management of fatigue in RA usually involves a 
combination of non-pharmacological and pharmacological strategies. There is evidence for 
effects of physiotherapy on fatigue, and in a meta-analysis, non-pharmacological therapies 
including physical activity and psychosocial intervention provide benefit in management of 
fatigue in patients with RA [88, 89]. Also pharmacological treatment, both DMARDs and 
biologic agents, have been shown to reduce fatigue [90]. However, it is important to 
acknowledge that fatigue is not clearly related to systemic inflammation as measured by CRP 
and ESR, but instead there is a strong correlation to pain [82]. The treatment effects on fatigue 
by DMARDs and biologics have thus often been linked to improvement in pain [82, 91, 92]. 
 
1.6 AUTONOMIC REGULATION OF INFLAMMATION 
The autonomic nervous system (ANS) is an important regulatory system participating in 
maintenance of homeostasis, in cooperation with other systems, including endocrine and the 
immune system [93, 94]. The ANS forms important links for neuro-immune regulation, both 
sympathetic and parasympathetically mediated [94] , The ‘cholinergic anti-inflammatory 
pathway’ is a well-documented neuro-regulatory mechanism, known as the inflammatory 
reflex [95, 96]. Briefly, afferent neurons of the vagus nerve sense inflammation in the periphery 
and signal to efferent vagal neurons in the nucleus tractus solitarius (NTS) of the 
brainstem.[97]. The activation of efferent signals in the vagal nerve causes release of 
norepinephrine from nerve endings in the spleen, and this elicits subsequent acetylcholine 
production from T-cells, subsequently leading to nicotine acetylcholine receptor subunit a7 
(nAChRa7) dependent down regulation of systemic pro-inflammatory cytokine production 
[98].  
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1.6.1 Autonomic nervous function in RA 
Several previous studies have reported dysfunction in the autonomic activity in patients with 
RA [99] , Moreover, autonomic dysfunction in RA has been shown to correlate with peripheral 
inflammation [100]  and nACRa7 is expressed in synovium of arthritis patients [101] . The 
findings of dysfunctional autonomic regulation in patients with RA has led to development of 
treatment strategies aimed at stimulating or restoring this pathway. For example, selective 
cholinergic agonists improve outcome in experimental models of arthritis [102]. Furthermore, 
recent pilot trials have used implantable pacemaker-like vagus nerve stimulating devices for 
the treatment of RA patients [103].  
1.6.2 Autonomic nervous function in FM  
The previously confirmed autonomic dysfunction in patients with fibromyalgia has been 
considered as mainly associated with pain and psychosocial stress [104] . FM autonomic 
dysfunction is associated with increased sympathetic activity and concomitantly reduced 
parasympathetic activity [105, 106]. However, autonomic dysfunction has not earlier been linked 
to neuroinflammatory processes. 
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2 AIMS OF THE THESIS 
2.1  GENERAL AIM  
The general aim was to investigate the patterns of pain and fatigue in early RA. Moreover, 
the relation between pain and inflammation was an objective, as well as an analysis of central 
nervous mechanisms in RA and FM in relation to autonomic activity. 
2.2 SPECIFIC AIMS  
1. To investigate pain patterns in newly diagnosed RA after three months treatment with 
DMARD, with special focus on patients who had achieved good clinical response. 
 
2. To  investigate whether  pain that remains after adequate antirheumatic treatment 
leading to inflammation control is a risk factor for later developing widespread pain, 
and fatigue. 
 
3. To study the association between pain and inflammation at different time points 
during the course of early RA. 
 
4. To investigate autonomic activity in patients with RA and FM compared to controls 
in relation to serum and neuroinflammatory mediators. 
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3 PATIENTS AND METHODS 
This thesis includes three epidemiological, observational studies and one clinical case-control 
study. The epidemiological studies are based on cases reported to a population-based early 
RA (EIRA) cohort who had follow-up data from the Swedish Rheumatology Quality 
Register (SRQ). An overview of the different patient cohorts in paper I-IV is presented in 
table 7. 
Table 7. Overview of patients in the studies of the thesis. 
 
 Paper I Paper II Paper III Paper IV 
Diagnosis RA RA RA RA, FM, HC 
Total no. 1242 408 2808 14; 15; 15 
Description, 
patient 
cohorts 
EIRA: MTX 
monotherapy 
from diagnosis / 
SRQ 
EIRAU3 / SRQ EIRA/SRQ RA: Outpatients at the 
Rheumatology clinic 
FM: Outpatients at the 
Department of 
Rehabilitation Medicine, 
HC: Recruited by 
advertising 
Age 56 (46-63)    <40 (18%) 
40-50 (14%) 
51-60 (25%) 
61-70 (37%) 
     >70 (5%) 
   <40 (18%) 
40-50 (19%)     
51-60 (31%) 
61-70 /30%) 
     >70 (2%) 
RA: 51 (36-59) 
FM: 46 (25–60) 
HC: 44 (25–61) 
Female, no 
(%) 
862 (69%)    300 (74%)  1840 (71%) RA: 14 (100%) 
FM: 15 (100%) 
HC: 16 (100%) 
VAS pain at 
baseline  
54 (IQR 35-71) 55 (IQR 32-73) 52 (IQR 33-70) RA: 24 ± 18 (mean±SD) 
FM: 66 ± 13 (mean±SD) 
HC: NA 
 
3.1 THE EIRA STUDY  AND LINKING TO THE SRQ REGISTER (PAPER I-III) 
The population of RA patients was evaluated from the Epidemiologic Investigation of 
Rheumatoid Arthritis (EIRA) which is a population-based case-controlled study, 
investigating possible risk factors of rheumatoid arthritis (RA) and increase understanding of 
which factors contribute to the development of this disease [107, 108]. The EIRA study includes 
incident RA patients, all fulfilling 1987 ACR criteria for RA [108]  and was initiated in 1996.  
The research project is up and running and EIRA has underwent three phases (referred to as I 
(1996-2006), II (2007-2016) and soon III will start, including modification of the 
questionnaires and modernization of the recruitment process). Thus, the study is still 
enrolling new cases and controls. Starting 2007, all participants also received a follow-up 
questionnaire 1 and 3 years after inclusion, EIRAU1 and EIRAU3, which include for example 
assessments of pain, fatigue, sleep problems (see below) and self-reported work capacity. 
Overall, the EIRA investigation is facilitated by linking to national follow-up system, the 
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Swedish Rheumatology Quality register (SRQ) for serial clinical data during the course of 
RA. The patients examined at 0, 3, 6, 9, 12, 18, 24, 36 and 60 months including joint 
assessment, function, disease activity and DAS28 - EULAR response [44, 109, 110] .  
3.2 RA, FM PATIENTS AND HEALTHY CONTROLS IN PAPER IV 
RA patients were outpatients at the Unit of Rheumatology, Karolinska University Hospital, 
Stockholm and fulfilled both the 1987 and 2010 ACR criteria for RA and none fulfilled the 
ACR criteria for fibromyalgia. For further baseline characteristics see table 7 and paper IV. 
No NSAIDs were administered within 24 h before CSF sampling and pain and fatigue 
assessments. No RA patient had any neurological disease.                                                     
FM patients were outpatients at the Department of Rehabilitation Medicine, Danderyds 
Hospital, Stockholm and fulfilled the classification criteria of the American College of 
Rheumatology (ACR) 1990 for fibromyalgia. For further baseline characteristics see table 7 
and paper IV. All the patients had normal erythrocyte sedimentation rate, hematology count, 
liver enzymes, creatinine kinase, thyroid function, rheumatoid factor and antinuclear 
antibodies. No medications were taken on a regular basis and no analgesics or non-steroidal 
anti-inflammatory drugs (NSAIDs) had been used on the day of assessment. None of the FM 
patients had other known painful conditions or neurological diseases.                                
Fifteen healthy sex- and age-matched subjects participated as controls in the study. They 
were assessed in the same way as the FM/RA patients except that no lumbar puncture was 
performed (for ethical reasons). The subjects were recruited by advertising at public places at 
Danderyds Hospital. 
3.3 PAIN ASSESSMENT (PAPER I-IV) 
Due to its multi-facetted appearance a fully objective measurement of pain is not possible. 
There are a number of pain assessment tools in the literature, including multi-item and 
multidimensional tools [111-118] .The VAS scale has been validated in RA [119-122] and provide a 
simple easy-to-use tool that is also implemented in the daily work of rheumatology care . 
Patients included in paper I-IV measured their present pain intensity on a visual analogue 
scale (VAS) (figure 4), where the responses were on a continuous range from 0 (no pain) to 
100 (worst pain). The line was not marked, and patients were unable to see their previous 
responses.  
Figure 4. Visual analog scale (VAS) pain 
 
Worst possible  
pain 
No pain 
0 10 
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3.4 REMAINING PAIN (PAPER I&II) 
Remaining pain (paper I) was defined as VAS pain >20 mm (Figure 5). Above this cut-off 
was previously described as a significant pain. This cutpoint has ealier been validated by 
(Wolf  F). definings VAS pain < 20mm as an acceptable pain level [119] . The concept 
remaining pain depicted significant pain after 3 months’ treatment with methotrexate in paper 
I and after one-year treatment with DMARDs in paper II.  
Figure 5. Remaining pain 
 
 
 
 
 
 
 
3.5 WIDESPREAD PAIN (PAPER II) 
Widespread pain (WSP) was defined based on the EIRAU1 and EIRAU3 follow-up 
questionnaires of pain outside joints. In the questionnaire, the patients who answered yes to 
the question on whether they were affected by pain outside their joints were asked to indicate 
all areas affected by pain outside the joints on a schematic drawing of a body (figure 6). The 
drawing was divided into 24 smaller areas (six per quadrant); the right and left part of the 
torso, the abdomen, the lower part of the back and the upper part of the back, respectively, 
and the dorsal and ventral part of each extremity (the lower leg, the upper leg/hip, the 
forearm, the arm/shoulder). The line dividing the upper and lower part of the body was drawn 
at the level of the end of the sternum. The question was specifically directed to pain outside 
joints and the peripheral joint regions (ankle/feet, knee joint, elbow joint and wrist/hands) 
were not possible to mark on the drawing. Patients were considered to fulfill the requirements 
for widespread pain if they assessed pain outside joints in one or more areas in all four 
Remaining pain 
Significant pain (VAS > 20mm)  
 
Worst  
possible  
pain 
No 
pain 
Significant pain 
       Cut-off  
Worst possible pain No pain 
0 10 
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quadrants of the body. Patients who had pain outside joints, and marked pain in at least one 
area were defined has having regional pain. Patients with WSP at one-year follow up 
(EIRAU1) were excluded in the prediction analysis for WSP and other clinical outcomes in 
EIRAU3. 
 
Figure 6. Schematic drawing from EIRAU1 and EIRAU3 questionnaire of body areas for 
assessment of pain outside joints. 
 
 
 
 
 
 
 
 
 
3.6 PATIENT ACCEPTABLE SYMPTOM STATE AND UNACCEPTABLE PAIN 
(PAPER III) 
 
Patient Acceptable Symptom State (PASS) has been defined as the highest level of 
symptom beyond which patients consider themselves well [123]. The PASS value is a 
clinically relevant cutoff from the patient's perspective, as being in “an acceptable state” (with 
the outcome score < the PASS) or not (with the outcome score > the PASS). In a study on 
osteoarthritis pain, the PASS was found more relevant than the minimal clinically important 
improvement outcome (MCII) which  recognise a clinically relevant improvement and 
reflects the concept of improvement (“feeling better”) [124] . This study thus concluded that 
patients experienced an important improvement only if this improvement allowed them to 
achieve a state they consider satisfactory. The cut-off for PASS concerning pain in 
 
 
 26 
rheumatic diseases has previously been validated as 40 mm on a pain VAS scale (figure 7) 
[123]. 
In study III we used the outcome of “unacceptable pain” which was defined as having VAS 
pain higher than what is defined by PASS, i.e. ≥ 40 mm on a VAS scale. [123, 125, 126]. 
 
 
 
 
Figure 7. Unacceptable pain  
 
 
 
 
 
 
 
 
 
 
3.7 FATIGUE AND SLEEP ASSESSMENTS (PAPER I-IV) 
Several methods of evaluation have been used to investigate fatigue in RA . Multidirectional 
scales developed to include the different aspects of fatigue, such as the Short Form 36 (SF-
36), the Functional Assessment of Chronic Illness Therapy Fatigue Scale FACIT [127], the 
RA-specific Multidimensional Assessment of Fatigue (MAF) scale, the Fatigue Severity 
Scale (FSS) [128]   and the Multidimensional Fatigue Inventory 20 item general (MFI-20). MFI-
20 covers 5 dimensions of fatigue: general fatigue, physical fatigue, reduced activity, mental 
fatigue, and reduced motivation (scores within the 5 dimensions range from 4 to 20 , with 
higher scores indicating higher levels of fatigue) [129, 130]. A simple, but useful method to 
evaluate fatigue is the visual analog scale (VAS, scores from 0-100, the higher score, the 
greater the fatigue). This single item scale has earlier been validated and described as more 
Worst possible pain No pain 
0 10 
Worst  
possible  
pain 
No 
pain Unacceptable pain 
PASS 
Cut-off 
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sensitive than longer scales [131, 132]. In this thesis, fatigue VAS was used in paper II and MFI-
20 in paper IV. For sleep assessments in paper II, we used assessment from the EIRAU3 
follow-up questionnaires. The following question was asked to the participant; “To what 
extent is sleep a health problem to you? 1. Very large problem, 2. Quite large problem, 3. 
Neither large nor small, 4. Small problem, 5. No problem”. In the analysis, sleeping problems 
were assessed as having 1 and 2 (paper II). Sleep disturbance was assessed using (Pittsburg 
Sleep Quality Inventory) PSQI [133] (paper IV). Physical and mental component of health 
related quality of life short form (SF-36) [134] was used in paper  IV.  
3.8 MEASURING CYTOKINES IN PERIPHERAL BLOOD AND             
CEREBROSPINAL FLUID (PAPER IV) 
Venous puncture was performed for collecting blood from both patients and controls and 
lumbar puncture was performed for collection of cerebrospinal fluid (CSF) from patients 
only. CSF samples were immediately centrifuged, supernatants frozen and stored in -80°C 
until use. Cytokine levels in CSF and serum were analyzed with ELISA (R&D, high 
sensitivity Quantikine). Sensitivity, expressed as the mean of minimum detectable dose 
(MDD), for the ELISA kits were as follows: IL-1β 0.14 pg/mL; IL-1ra: 6.26 pg/mL; IL-4: 
0.11 pg/mL; IL-5 0.29 pg/mL; IL-6 0.039 pg/mL; IL-8 3.5 pg/mL; IL-10 0.09 pg/mL; TNF 
0.106 pg/mL. Human CSF was tested for CCL-2 (Cat No L451AYA-1), BDNF (Cat No 
N45ZA-1), and β-NGF (custom made prototype), in a chemiluminiscence assay based on the 
MSD technology (Mesoscale Discovery, Gaithersburg, MA, US). Samples were captured on 
pre-coated MSD plates and detected using a labelled biotinylated antibody directed towards 
the analyte of interest. 
3.9 HEART RATE VARIABILITY (PAPER IV) 
Heart rate variability (HRV) is used in clinical research to measure the activity and integrity 
of the autonomic nervous system [135]. To measure HRV, 24-hour Holter recordings were 
applied for 24 hours’measurements [136] (figure 8). Recordings were manually read, and 
readings with a high number of ectopic beats were discarded from analysis.  
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 HRV contains 2 domains: time domain and frequency domain [137]. The component that were 
included in the study were the major components of the time domain, the root mean square of 
the standard deviation between normal-to-normal (NN)-intervals (RMSSD) and the standard 
deviation of intervals between successive QRS complexes (SDNN) are considerd to be 
indicators of parasympathetic tone [138] .The frequency domain (power spectral) analysis of 
heart rate variability allows identification of component frequencies of the heart rate 
spectrum. The components of the frequency domains includes: the high-frequency (HF) 
component of the heart rate spectrum, considered to reflect parasympathetic influence on the 
heart rate, while the low-frequency (LF) component has been shown to include contributions 
from both the sympathetic and parasympathetic nervous system [139] . The HF/LF ratio 
indicate balance between sympathetic and parasympathetic nervous system  [99]. (Table 8). 
Table 8. HRV components included in paper IV  
RMSSD (ms) vagal influence on HRV 
SDNN (ms) vagal influence on HRV 
LF (ms2) Sympathetic influence, but also including a parasympathetic 
component 
 HF (ms2) Only parasympathetic influence 
LF/HF Indicator of autonomic balance 
 
 
 
 
 
Figure 8. Holter ECG 
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3.10 STATISTICAL METHODS 
Paper I: The association between baseline parameters and remaining pain was evaluated by 
logistic regression and expressed as odds ratios (OR) with 95% confidence intervals 
(95%CI), adjusted for age at diagnosis (treatment start) and sex. IBM SPSS version 21 was 
used for all statistical analyses. 
Paper II: The correlation between remaining pain at 1 year and patient-reported fatigue (>40 
mm on a visual-analog scale), regional pain (pain outside joints in at least one area), wide-
spread pain (pain outside joints in at least one area in each of the four quadrants of the body), 
and sleeping problems (reported by the patient as “quite large” or “very large”) at the 3 year 
follow-up was evaluated by modified Poisson regression [140]. The analysis was performed 
both crude and adjusted for sex, age and calendar period of RA-diagnosis. All analyses were 
carried out using SAS Statistical Package 9.3. 
Paper III: The correlation between pain, DAS28 and its components was assessed at the time 
points 0, 3, 6, 12, 48 and 60 months, by using Pearson’s correlation and the confidence intervals 
were assessed using Fisher’s transformation. A Kaplan-Meier analysis was run using the 
survival package [141] to investigate the time to reach stable state of PASS continuous data for 
the first five years. In this analysis, we defined a stable state of PASS as two consecutive visits 
with a VAS pain below 40 mm. The time to event was defined as the time to the second of the 
two visits with VAS pain below 40 mm. The association between baseline parameters and 
unacceptable pain at one year was assessed using modified Poisson regression and expressed 
as relative risk ratios with 95% confidence intervals (95%CI), adjusted for sex and age at 
diagnosis. All statistical analysis in this paper was made using R, except demographics where 
IBM SPSS version 21 was used. 
Paper IV: Overall group differences between patients with FM, RA patients and HC were 
analysed by Kruskal-Wallis Test and post hoc group differences were assessed by 
Independent Samples Mann-Whitney U-test. Correlations were analyzed by Spearmans’ 
correlation coefficient. P < 0.05 was considered as a statistically significant difference. 
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4 RESULTS  
4.1 REMAINING PAIN IS COMMON IN EARLY RA (PAPER I) 
The study base consisted of 1241 patients with early RA from the EIRA cohort, who also had 
follow up data from SRQ. Information about VAS pain and DAS28 were available for 1063 
patients at 3 months follow up visit. All patients were initially under treatment with 
methotrexate as a monotherapy. The frequency of the three response groups according to the 
EULAR response criteria [44] are displayed in figure  9. 
Figure 9. Frequency of EULAR response to treatment at 3 months follow up. 
 
Remaining pain was observed in 58% of all patients and 29% in the good response group 
(GR), 70% in the moderate (MR) and 83% in the non respose group (NR) at the 3 months’ 
follow-up visit. In the whole group, remaining pain at 3 months follow up visit was 
significantly associated with the following baseline parameters: higher baseline disability 
score HAQ (OR 2.17 (1.74-2.71) ), higher PGA (OR 1.02 (1.01-1.02)), higher CRP (OR 1.05 
(1.02-1.10)), higher TJC (OR 1.05 (1.03-1,07)), higher DAS28 (OR 1.32 (1.19-1.48)) as well 
as lower age (OR 0.98 (0.97-0.99)), while there were no significant association between sex, 
ACPA, RF, SJC, smoking and remaining pain. 
In the EULAR good response group, remaining pain was significantly and positively 
associated to high baseline disability HAQ (OR 2.2 (1.4-3.4)) and PGA (OR 1.15 (1.05-
1.27)). Furthermore, remaining pain was associated with low baseline ESR (0.81 (0.70-
0.93)). Other baseline variables such as CRP, ACPA, rheumatoid factor, swollen and tender 
joint, smoking and DAS28 were not associated with remaining pain in the good response 
group. 
NR 
22.6% GR 
39.6% 
MR 
37.8% 
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During the treatment period, increase in VAS pain, defined as a higher VAS pain value at 3-
months follow-up compared to baseline, was observed in 19% of the whole cohort, and in the 
response groups the frequency of increasing in VAS pain, was 9% in the good response 
group, 15% in the moderate response group and 45% in the non response group. 
Increased pain in the whole cohort was associated to lower baseline HAQ (OR 0.57 (0.43-
0.75)) , lower ESR (OR 0.90 (0.84-0.97)), lower PGA (OR 0.83 (0.77-0.88)), presence of 
current smoking (OR 1.54 (1.09-2.18)), lower SJC28 (OR 0.96 (0.93-0.99)) , lower TJC25 
(OR 0.97 (0.95-0.99)) and lower DAS28 (OR 0.71 (0.62-0.81)).  
In the EULAR good response group, increased pain was associated to lower baseline HAQ 
(OR 0.25 (0.12-0.54)), lower PGA (OR 0.79 (0.68-0.92)), lower TJC25 (OR 0.90 (0.83-
0.99)) and lower DAS28 (OR 0.53 (0.36-0.79)). 
4.2 REMAINING PAIN IN SPITE OF INFLAMMATION CONTROL 
ASSOCIATES WITH LONG-TERM WIDESPREAD PAIN (PAPER II) 
The study included patients from the EIRA study that had received a 3-year follow-up 
questionnaire (EIRAU3), beginning in 2007. At the time of study analysis, information on 
785 RA patients was available. Specifically, the questionnaire included questions on pain 
outside joints, fatigue and sleeping problems. Moreover, a pain drawing was available for patients 
responding positive to the question of pain outside joints (see methods). 408 patients had data 
from both EIRA, SRQ and EIRAU3. Of those patients, 6% had wide-spread pain, 33% had 
regional pain, 19% had significant fatigue and 12% had sleeping problems.  
Remaining pain in spite of inflammation control was defined as VAS pain > 20 mm together 
with a CRP < 10 g/L. The frequency of remaining pain in spite of inflammation control at the 
one-year follow-up was 35% in the whole cohort. Remaining pain at one-year strongly 
increased the risk for wide-spread pain, regional pain and fatigue as shown in (table 9). 
Remaining pain at one-year did not statistically significant increase the risk for sleeping 
problems. 
Table 9. Relative Risk (RR) of remaining pain at one-year for development of wide-spread 
pain, regional pain, fatigue and sleeping problems after 3 years non-adjusted and * adjusted 
for sex, age at diagnosis of RA and calendar period of diagnosis of RA. 
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 N RR 95% CI RR* 95% CI 
Wide-spread pain  380 2.42 1.07-5.45 2.38 1.11-5.08 
Regional pain 285 1.75 1.41-2.18 1.67 1.33-2.09 
Fatigue 319 1.83 1.34-2.50 1.68 1.22-2.30 
Sleeping problems 357 1.47 0.97-2.24 1.36 0.88-2.10 
 
In absolute terms, the risk to have wide-spread pain and regional pain among the patients 
with remaining pain at 1 year after diagnosis, was 10% and 52% respectively, while in the 
patient group without remaining pain at one-year, the risk was 4% and 24% respectively. 
Importantly, subsequent analyses have further validated WSP at the 3-year follow-up. Thus, 
WSP was shown to associate with significantly lower levels of all domains of SF-36 
(Lindqvist J et al, Reumadagarna Umeå, 2016). 
4.3 PAIN PATTERNS IN EARLY RA (PAPER III) 
The purpose with paper III was to investigate the association between pain and inflammation 
during the course of early RA, and also to try to identify predictors of unacceptable pain. 
2808 patients from the EIRA study linked to the SRQ were included, 1840 (71%) were 
females and 1665 (66%) were anti-CCP positive.  
At three months’ follow-up there was a clear and significant decrease in median VAS-pain 
from 52 mm (IRQ 37) to 26 mm (IRQ 37) which remains relatively stable in the later on 
visits up to five years (six months (24 mm; IQR 38); twelve months (22 mm; IQR 41); 24 
months (22 mm; IQR 36) and five years (25 mm; IQR 39). 
First, we investigated the correlation between pain and DAS28 and its component at different 
time points (figure 10). There was a significant increase in correlation between pain and 
DAS28, SJC and TJC from baseline to three months’ visit, thereafter the correlation remains 
stable through the 6 months, 12 months, 24 months and five years visit, while the correlation 
between pain and PGA significantly increased from diagnosis to three months and continued 
to increase also at the 6 months’ visit. The correlation coefficient between pain and TJC was 
significantly higher than for SJC throughout the period (figure 10). The correlation of pain 
with CRP and ESR was relatively constant through-out the follow-up visits. 
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Figure 10. Correlation between pain and components of DAS28; 6 time-points from 
diagnosis to 5 years. 
 
 
Second, we investigated the proportion of patents not reaching stable acceptable symptoms 
state (stable PASS, for definition, see patients and methods). The proportion of patients 
reaching stable PASS at six months, one, two and five years is displayed in figure 11A . The 
proportion of women not reaching stable PASS was significantly higher than men, both after 
five years (19.5% vs 10%3%, p<0.0002), and during the whole disease course from diagnosis 
to five years later in the Kaplan–Meier analysis (figure 11B). 
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Figure 11A. Time to achievement of stable PASS. The 95% CI is marked with dashed lines 
 
 
Figure 11B. Time to achievement of stable PASS, men vs women. The 95% CI is marked 
with dashed lines. 
 
 
 
Last, we investigated the association between baseline parameters and unacceptable pain at 
one year and we found that higher disability, TJC and PGA associated with an increased risk 
for unacceptable pain, while higher SJC at baseline was associated with a decreased risk 
(table 10).  Moreover, there were significant trends for higher association with higher HAQ, 
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PGA and TJC. There were no association between anti-CCP (ACPA), nor baseline CRP and 
ESR and unacceptable pain at the one year follow-up (table 10). 
Table 10. Risk factors for unacceptable pain (VAS pain ≥40) at the one-year follow-up visit. 
Risk ratios (RR) with 95% confidence interval (95%CI), adjusted for age and gender. 
 
  N RR 95%CI P P for trend 
Anti-CCP           Negative 
Positive  
753 
1401 
0.99       
1.00 
0.86 - 
1.13 
Ref 
0.84  
HAQ at 
diagnosis   
(quartiles)   
0.0 - 0.5 
0.5 - 1.0 
1.0 - 1.5 
1.5 - 3.0 
499 
691 
515 
391 
1.00 
1.39 
1.69 
1.97 
Ref 
1.13-1.71 
1.38-2.08 
1.60-2.42 
 
0.0015 
5.8x10-7 
1.3x10-10 
 
  8.5e-13 
Swollen joint 
count  
(quartiles)     
  
≤5 
6-9 
10-13 
>=14 
608 
593 
480 
501 
1.00 
0.93 
0.80 
0.79 
Ref 
0.79-1.09 
0.66-0.95 
0.66-0.95 
 
0.36 
0.014 
0.011 
 
  0.0044 
Tender joint 
count  
(quartiles)     
           
≤4 
5-8 
9-12 
>13 
692 
558 
453 
512 
1.00 
1.06 
1.24 
1.40 
Ref 
0.88-1.27 
1.03-1.49 
1.18-1.65 
 
0.56 
0.020 
9.2x10-5 
 
  2.0e-5 
C-reactive 
protein 
(quartiles)   
<10 
10-19, 
20-29 
30-39 
>=40 
815 
501 
258 
144 
402 
1.00 
0.90 
0.89 
0.86 
0.85 
Ref 
0.76-1.06 
0.72-1.10 
0.65-1.14 
0.70-1.03 
 
0.21 
0.27 
0.30 
0.094 
 
 
  0.066 
ESR 
(quartiles)   
<10 
10-20, 
20-30 
30-40 
>=40 
286 
508 
396 
291 
625 
1.00 
0.90 
0.86 
0.86 
0.83 
Ref 
0.73-1.10 
0.69-1.08 
0.68-1.09 
0.68-1.03 
 
0.31 
0.20 
0.22 
0.085 
 
 
   0.25 
Patient global 
assessment 
(quartiles)   
<20 
20-40 
40-60 
60-80 
>80 
310 
420 
594 
530 
285 
1.00 
1.34 
2.07 
2.14 
2.63 
Ref 
0.98-1.82 
1.58-2.73 
1.62-2.83 
1.98-3.49 
 
0.063 
1.9x10-7 
7.4x10-8 
1.8x10-11 
 
 
  < 2.2e-16 
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In total, 30.8% of the patients had unacceptable pain at one-year visit, this group of patients 
had significantly higher DAS28, CRP, ESR, SJC, TJC, PGA and HAQ compared to the 
group of patients reaching PASS. However, there were no differences in ACPA status and 
current smoking between the groups (table 11). 
Table 11. Clinical characteristics for patients with fulfillment of an acceptable symptom state 
(PASS) vs unacceptable pain. 
 
 PASS          Unacceptable 
pain    
P  
Total N   1603     715  
Women N   1022      493  
DAS28 (Mean ± SD) 2.5  (±1.14) 4.1 (±1.3) < 0.001 
CRP (Mean ± SD) 8.1 (±11,2) 13.3 (±18.5) < 0.001 
ESR (Mean ± SD) 14.4 (±12.4) 20.2 (±17.5) < 0.001 
SJC (Mean ± SD) 1.4 (±2.6) 3.5 (±4.1) < 0.001 
TJC (Mean ± SD) 1.5 (±2.8) 5 (±5.3) < 0.001 
PGA (Mean±SD) 16.9 (±16) 55.4 (±19.1) < 0.001 
HAQ (Mean±SD) 0.32 (±0.4) 0.98 (±0.54) < 0.001 
ACPA positive (N (%)) 965 (66%) 432 (66%) NS 
Current Smokers (N (%)) 458 (31%) 206 (31%) NS 
Biologics (total) (N (%)) 224 (14%) 150 (21%) < 0.001 
 
4.4 PERIPHERAL AND CENTRAL NERVOUS INFLAMMATION – RELATIONS 
TO AUTONOMIC FUNCTION (PAPER IV)  
This clinical study is a comparative investigation of pain, fatigue, peripheral and central 
nervous inflammation in patients with RA, FM and healthy controls. Compared to RA 
patients, patients with fibromyalgia rated significantly higher pain intensity. Furthermore, 
patients with FM had a significantly higher rating of fatigue and sleep problems as well as 
lower mental and physical quality of life than RA patients. When comparing RA with 
controls, RA patients had a significantly higher rating of fatigue and sleep disturbance as well 
as significant lower mental and physical quality of life (Table 12). 
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Table 12. Differences in  clinical characteristics between patients with FM, RA and controls.  
Average & SD FM patients RA patients  Healthy 
controls  
Group 
differences 
Age 46.2  11.1 
n = 15 
51.1  7.2 
n = 14 
44.4  10.7 
n = 15 
NS 
Duration 
FM/RA (years) 
2.9  2.7 
n = 15 
8.4  8.7 
n = 14 
NA P < 0.028 
Pain (mm VAS) 65.8  13.2 
n = 15 
24.0  18.0 
n = 14 
NA P < 0.001 
Fatigue (MFI-
20) 
18.1  1.4 
n = 15 
14.0  4.2 
n = 14 
5.1  1.0 
n = 15 
P < 0.001 
Sleep (PSQI) 13.2  3.7 
n = 15 
6.6  3.0 
n = 13 
1.8  1.7 
n = 15 
P < 0.001 
SF-36 phys 26.4  7.6 
n = 15 
62.4  18.6 
n = 14 
97.5  2.7 
n = 15 
P < 0.001 
SF-36 ment 40.3  21.2 
n = 15 
72.5  21.6 
n = 14 
90.4  6.3 
n = 15 
P < 0.001 
Analysis of cytokine/chemokine levels in serum and cerebrospinal fluid (CSF) was 
performed in patients only. We found both patients with RA and FM had significantly lower 
concentration of TNF and IL-1β in serum compared to healthy controls. Furthermore, RA 
patients had lower levels of these cytokines in serum compared to patients with FM. 
Moreover, the concentration of IL-8 in serum was significantly higher in patients with FM 
compared to RA patients and healthy controls, while RA patients had significant lower levels 
of IL-8 compared to controls. Further, RA patients had higher concentration in serum IL-6 
compared to controls (Table 13). 
Table 13. Serum cytokines concentrations in FM patients, RA patients and healthy controls. 
Overall group differences are shown. Statistically significant differences between FM and RA 
patients are marked † and significant differences between controls and patients are marked ‡. 
P < 0.05 is regarded as a statistically significant difference. SD = standard deviation 
Serum levels 
(pg/mL) 
Means ± SD 
FM RA Controls Group 
differences 
IL-1β 0.59±0.08‡ 
n = 15 
0.02±0.06†‡ 
n = 13 
0.83±0.24 
n = 15 
P < 0.001 
IL-8 21.36±5.54‡ 
n = 15 
10.42±6.68†‡n 
n = 12 
16.58±6.20 
n = 15 
P < 0.001 
TNF 2.77±1.61‡ 
n = 14 
1.41±0.96†‡ 
n = 13 
4.42±2.29 
n = 15 
P < 0.001 
IL-6 1.45±0.76 
n = 14 
7.50±16.07‡ 
n = 14 
1.21±0.70 
n = 15 
P = 0.054 
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In the cerebrospinal fluid, RA patients had significantly higher IL-1β and lower IL-1Ra 
compared to FM patients (table 14). Controversely, FM patients had higher CSF levels of IL-
8 and anti-inflammatory cytokines IL-1Ra, IL-4 and IL-10 compared to RA. There was a 
tendency to higher levels of TNF in CSF in FM patients compared to RA. No significant 
differences were found in CSF levels of IL-6 and CCL-2 between the two groups. The levels 
of chemokines BDNF and NGF were undetectable in CSF of both FM and RA patients 
(Table 14).   
Table 14  Concentrations of cytokines and chemokines in cerebrospinal fluid of FM and RA 
patients. Overall group differences are shown. P < 0.05 is regarded as a statistically 
significant difference. SD = standard deviation. 
 
CSF levels 
(pg/mL) 
Means ± SD 
FM RA Group 
differences 
IL-1β 2.58 ± 1.98 
n = 14 
8.83 ± 7.21 
n = 14 
p = 0.002 
IL-8 62.35 ± 26.26 
n = 14  
26.92 ± 14.07 
n = 12 
p < 0.001 
TNF 0.38 ± 0.22 
n = 14 
0.26 ± 0.09  
n = 14 
NS (p = 0.056) 
IL-6 1.80 ± 0.69 
n = 14 
1.60 ± 0.73 
n = 14 
NS 
CCL-2 439.03±114.54 
n = 12 
491.43±134.74 
n = 13 
NS 
IL-1Ra 27.50+4.96 
n = 14 
17.06+9.82 
n = 14 
p = 0.002 
IL-4 0.25+0.20 
n = 14 
0.04+0.05  
n = 14 
p < 0.001 
IL-10 0.43+0.19 
n = 14 
0.13+0.08 
n = 14 
p < 0.001 
 
Regarding the autonomic activity, both RA and FM patients had significantly higher heart 
rate compared to controls (table 15). There was a decrease in HF in RA compared to controls 
in line with the decrease parasympathetic activity in RA. In FM there was increased LF/HF 
ratio in line with increased sympathetic activity in FM (Table 15).  
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Table 15. Heart rate variability data in patients with RA and FM as well as HC. 
Means ± SD FM RA Healthy 
Controls 
Group 
differences 
Heart rate (bpm) 78+10‡ 
n = 15 
75+6‡ 
n = 14 
68+5 
n = 15 
p = 0.003 
RMSSD (ms) 30.9+12.2‡ 
n = 15 
29.2+8.1‡ 
n = 14 
50.7+24.8 
n = 15 
p = 0.002 
SDNN 124+24.9‡ 
n = 15 
127.8+27.6‡ 
n = 14 
152.9+33.0 
n = 15 
p = 0.02 
LF 836+541 
n = 15 
530+213‡ 
n = 13 
948+523 
n = 15 
NS 
HF 410+259 
n = 15 
313+280‡ 
n = 13 
759+657 
n = 15 
p = 0.018 
LF/HF 3.41+1.30‡ 
n = 15 
2.65+0.71 
n = 13 
2.23+1.0 
n = 15 
p = 0.036 
 
In RA patients, the time-domain component SDNN correlated negatively with serum IL-6 (r= 
 ̶  0.868 p<0.0001) and CSF IL-10 (r=  ̶  0.716 p=<0.006). Regarding the frequency-domain, 
RA CSF IL-1β correlated positively with LF/HF (r=  ̶  0.64 p<0.05), morover, CSF IL-10 
displayed an inverse correlation with LF (r=  ̶  0.58 p<0.05). In serum, IL-6  correlated 
inversely to LF (r=  ̶  0.55 p<0.05). 
In FM patients, serum IL-1β correlated inversely to SDNN (r=  ̶  0.646 p<0.01). No 
significant correlations was found between other serum nor CSF cytokines and HRV. 
  
 40 
5 GENERAL DISCUSSION  
Musculoskeletal pain is a major symptom affecting quality of life in arthritis patients. The 
main finding of this thesis is that pain remains despite inflammatory control in early RA. The 
first three epidemiological studies in this thesis had main focus on pain in early RA patients 
and the risk for later development of wide spread pain. The fourth clinical study had main 
focus on central nervous inflammation and autonomic function and found differences in these 
mechanisms between RA and the dysfunctional pain condition, fibromyalgia. Moreover, CNS 
inflammation were connected to autonomic function in RA.  
5.1 REMAINING PAIN IN RA 
Pain VAS scale (0-100mm) has been used widely as a simple clinical measurement of pain 
intensity and the assessment of VAS pain >20 mm was previously stated as a cut-off for 
patients with RA reporting significant pain[119].  In order to discriminate between pain 
associated with inflammation and pain affecting the RA course, we first aimed to define the 
state of significant pain frequency when patients had received the first-line treatment with 
MTX during three months, i.e. when a majority of patients are expected to have responded 
clinically to the drug.  In our cohort, we found remaining pain in 58% patients with early RA 
after 3-month treatment with methotrexate as a standard DMARD (paper I). Notably, 
previous data from an international observational study that included patients with both early 
RA and established disease [142] , reported high frequency of dissatisfaction with pain in spite 
of effective immune-suppressive therapies. Although our study included only patients with 
early RA,  there was a similarity in pain frequency. This is in line with patients suffering from 
pain in spite of antirheumatic treatment in both early and late RA. Moreover, earlier data has 
shown discrepancy between decreased inflammation and pain [143] and that pain persists, even 
among individuals in remission as measured by the DAS28 criteria [144]. In paper I, we 
therefore focused on investigating pain in a group of RA patients with good clinical response 
to treatment according to EULAR response criteria [145]. Our data shows that almost one-third 
of RA patients with good inflammatory response to treatment with methotrexate as a 
monotherapy at 3-months follow-up reported remaining pain defined as above. In this group, 
remaining pain was associated with high baseline disability and low systemic inflammation, 
as measured with ESR. These results are in line with earlier reports of strong association 
between pain and functional impairment [146] and also that high inflammation or disease 
activity at baseline is not predictive for development of pain that persist although 
inflammation is suppressed. 
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The uncoupling between pain and inflammation is further supported by several other reports. 
Thus, McWilliams et al showed lack of pain improvement after one year of treatment [147] and  
a recent publication showed that a majority of the RA patients with high pain rating had 
minimal signs of inflammation [91] . Moreover, increased pain behavior was detected in 
experimental arthritis also remaining after the inflammatory phase of the disease [148]. Our 
results are also in line with the earlier reports of relation between peripheral joint 
inflammation and development of pain sensitization (see introduction, pain in RA). Pro-
inflammatory cytokines like tumor necrosis factor (TNF) and interleukin 6 (IL-6) affect pain 
thresholds in experimental arthritis as well as long-term sensitization of joint nociceptors. 
Inflammatory impact on the peripheral nerves may thus lead to long-term sensitization, which 
may contribute to development of chronic pain. However, the further course of pain seem to 
be uncoupled from the inflammatory course of the disease. This was also supported by the 
findings in paper III that inflammation and inflammation markers are less coupled to pain 
when patients have been adequately treated with antirheumatic agents. In paper I we could 
also note interesting differences concerning predictive factors between all patients treated 
with MTX and the EULAR good response group. In both groups, high disability and high 
PGA was predictive. Baseline high disease activity and inflammation was predictive only in 
the former group, which is in line with inflammation contributing to remaining pain in some 
patients at the 3-month follow-up. In the latter group, however, this coupling is lost, which 
suggest that long-term pain sensitization is not the result of high inflammatory disease from 
diagnosis, but rather other factors may contribute to development of chronic pain in this 
context..  
5.2 REMAINING PAIN AND WIDESPREAD PAIN 
Another objective with the studies of pain was to investigate the long-term consequences of 
remaining pain and the impact on other patient-reported outcomes (PROs) such as fatigue. 
The purpose with these studies was also to define a simple, easy-to-use, outcome for pain in 
spite of inflammation control (after adequate antirheumatic treatment), that could be related 
to the potential presence of long-term pain and fatigue during the course of early RA. For 
general purposes, and with the use of different initial treatment strategies (i.e. MTX 
monotherapy, MTX + prednisolone, combinations with other DMARDS (triple therapy) or 
biologics in some patients), we found a need to define a new follow-up time - one year after 
diagnosis - when we considered the antirheumatic treatment to have resulted in optimized 
inflammatory control of the disease. We therefore modified the definition of remaining pain 
in paper II with the follow-up time of one year and the addition of CRP<10, as an objective 
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marker of inflammation control. For note, we had also used this parameter in a sensitivity 
analysis in paper I, confirming the results of predictive baseline factors in patients with good 
clinical response. In paper II remaining pain in spite of inflammatory control at one year 
follow up was observed in more than a third of the early RA patients. These findings are well 
in line with the frequency of pain related to good clinical response from paper I, and confirm 
that non-inflammatory factors contribute substantially to pain after antirheumatic treatment.  
After defining remaining pain in spite of inflammatory control, the next step was to 
investigate if this registry-based measurement could be useful for prediction of long-term 
pain conditions connecting to RA and widespread pain (WSP). In the ERIAU3 follow-up 
cohort, data on pain outside joints was then combined with data from pain drawing as 
described (paper II). In order to assess the development of the pain condition, we also 
excluded patients fulfilling the outcome of WSP at one year. Our finding that remaining pain 
in spite of inflammatory control strongly predicted development of WSP supports the 
hypothesis that pain that remains after optimized inflammation is unlikely to improve, and 
also increase the risk of generalization of pain also outside joints. This stabilization of pain 
levels is concurrent with our findings in paper III, and depicts a further understanding of pain 
patterns in early RA. Notably, the frequency of our reported WSP is 6%, which is comparable 
to the frequency of fibromyalgia earlier reported in early inflammatory arthritis [149]  This 
strengthens the validity of WSP as mirroring generalized pain, however since we do not have 
serial follow-up data, we can not define this condition as chronic widespread pain. In a later 
investigation, we have further validated the impact of our WSP-definition, showing that 
patients with WSP (according to the same definition) reported significantly lower levels in all 
SF36-domains (Lindqvist J et al, Reumadagarna, Umeå, 2016). Thus, these data confirms the 
validity of WSP as a measurement of general pain outside joints that is also associated with 
reduced physical and mental health. The importance to assess chronic and widespread pain in 
RA should not be underestimated. Thus, patients with RA and concomitant fibromyalgia 
report worse functional status and quality of life than RA patients without fibromyalgia [150] 
[151] . Moreover, our studies have shown that also simple, and clinically highly implemented, 
pain assessement coupled with markers of inflammation may be used to define patients with 
an increased risk for development of potentially severe pain conditions. Therefore, the 
definition of remaining pain in spite of inflammatory control could be utilized for early 
intervention in risk groups, which is an objective for further registry-based and clinically 
relevant research.   
Chronic widespread pain is a component of FM, and the investigation of central nervous 
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mechanisms in FM compared to RA was also an aim of the thesis. In order to investigate 
potential differences between RA and FM, known to be associated with dysfunctional pain 
regulation, paper IV focus on central nervous inflammatory mediators in both these diseases. 
We then found evidence of different CSF cytokine profiles in these diseases with an 
upregulation of IL-1β in RA and IL-8 upregulation in FM. Moreover, we found differences in 
autonomic regulation, further described below. Interestingly, earlier experimental studies 
have revealed that IL-1β and IL-8, who are both produced by glia cells contribute to pain and 
hyperalgesia through different pain mechanisms [51, 152] . IL-1β  injected intrathecally 
stimulates COX-2 activity [153] and IL-1β mediated increase in pain sensitivity can be 
prevented by COX-2 inhibitors [154]. On the contrary, IL-8 induced increase in pain sensitivity 
is not reversible with COX-2 inhibitors, but instead, beta-adrenergic receptor antagonists or 
guanathedine [152] can block these effects. These data are also well in line with the inefficacy 
of COX-2-inhibitors in FM [155]. The exact mechanisms how these cytokines may affect pain 
regulation are not known, but our data are thus well in line with different profiles in central 
cytokine release in RA vs FM that may reflect disparate natures of pain regulation in these 
diseases. Thus, RA was characterized by an IL-1β dominated immune activation that can be 
associated with prostaglandin-mediated mechanisms, whereas the increase of IL-8 in FM is 
associated with pain regulatory mechanisms that are independent of prostaglandins, and 
rather sympathetically mediated. In conclusion, these data indicate that neuroinflammatory 
processes may be of utmost importance in chronic pain conditions, and support the 
development of therapies targeted to neuroinflammation and modulation of glia-mediated 
pain regulation. . 
5.3 PAIN PATTERNS IN EARLY RA  
In RA, there is a strong correlation between pain and disease activity at diagnosis [156], and 
this was also confirmed in our studies. Moreover, in paper III this correlation became 
stronger at the three months’ follow-up, and remained stable in the subsequent visits, in line 
with a stronger impact of pain on disease activity when inflammation is under control [144]. 
The correlations between pain and the objective inflammation markers were low at diagnosis, 
and remained low during subsequent visits, in accordance with a minor impact of 
inflammation on pain after adequate antirheumatic treatment [143, 157]. On the other hand, 
correlations between pain and swollen joint count / tender joint count significantly increased 
from diagnosis to three months. Interestingly, there was a significantly higher correlation 
between pain and tender joints vs swollen joints at all follow-up time points after three 
months. This is in line with a close connection between joint tenderness and subjective pain, 
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and important to acknowledge for disease monitoring. After three months, these correlations 
remained stable through the first year.  
The correlation between pain and patient global assessment was as expected very strong at 
diagnosis, but in contrast to all other measured clinical parameters continued to increase 
significantly also at the six month follow-up. Furthermore, in paper I these mesures at 
inclusion predict later remaining pain. These results are in line with earlier reports that pain 
has a major impact on the individual patient´s well-being [61]. In conclusion, general pain 
impact becomes more important when the disease has been adequately treated.  
5.4 UNACCEPTABLE PAIN AND PAIN COURSE IN RA 
The term remaining pain was identified as the minimal level where patients with early RA 
would have significant pain after adequate anti-rheumatic treatment. Interestingly, also this 
low cutoff was validated to predict widespread pain (paper II). However, clinically it is vital 
to also assess a state where patients report a pain that is not acceptable. This level of pain has 
earlier been validated and defined as patient acceptable symptom state (PASS). We therefore 
used this higher cutoff (VAS pain ≥ 40, unacceptable pain) and investigated the pain course 
in early RA. The finding that almost a third of patients had unacceptable pain one year after 
diagnosis is in line with our earlier observations in paper I & II, and also earlier reports [142, 
144, 147]. Next we investigated what baseline factors may predict unacceptable pain. We found 
strong impact of impaired function with an almost two-fold increased risk of having 
unacceptable pain after one year. Moreover, high TJC at diagnosis was predictive where high 
levels of SJC significantly predicted not having unacceptable pain. The latter data is also in 
line with the earlier described differences concerning tender vs swollen joints in the 
connection to pain experience.  
Patients with unacceptable pain at one year had significantly higher CRP, ESR and DAS28, 
indicating that there is also a significant remaining inflammation in this context. Interestingly, 
in the group that reached PASS, both SJC and TJC were at the minimum. Moreover, median 
DAS28 levels were close to remission levels, thus indicating that pain at this time point of 
disease is a major contributor to disease activity. On the contrary, in the group with 
unacceptable pain, the DAS28 median was 4.1, thereby clearly showing moderate disease 
activity in a majority of these patients. In this group disease activity is driven both by pain, 
but also apparently by inflammation, since the CRP and ESR levels also were significantly 
higher in the latter group. To support this, we also found that biologics were more commonly 
prescribed in the group with unacceptable pain. The differences between these groups likely 
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represent different phenotypes of RA, with markedly different functional capacity, and 
potentially large differences in the prognosis. It is thus vital that treatment in early RA should 
be directed both at adequate immune suppression, but also at decreasing pain, since this is a 
major symptom affecting functional impairment. 
We also followed the pain course during the first five years of disease. Here we could 
conclude that the achievement of acceptable pain is highest during the first year, correlating 
with the clinical response to therapy, but after the first year the additional achievement of 
acceptable pain in remaining patients decrease. There is a stabilization of pain after the first 
two years of disease, and a significant proportion, almost one fifth, of the patients continue to 
have stable high pain levels.  The proportion of women with unacceptable pain was higher 
than men at all studied time points, which is in line with the higher pain levels observed in 
general for women and female RA patients [158, 159]. There was however no other differences 
in the curve pattern for women vs men, and both showed a clear decrease of unacceptable 
pain between the three and twelve months follow-up, in line with no effects of sex on 
immune suppressive treatment effects on pain [160, 161]. 
5.5 FATIGUE IN RA 
Fatigue is common in RA, and confers important impact on quality of life and work capacity. 
As expected, we could confirm higher fatigue levels in RA compared to controls (paper IV), 
and also a higher ratings in sleep disturbance and mental and physical health (paper IV). 
However, both fatigue levels and sleep disturbances as well as mental and physical health 
were significantly worse in FM than in RA (paper IV), an observation that supports the 
importance of pain vs inflammation on fatigue, although other complex factors, such as 
disturbed CNS pain regulation are also likely to contribute. In the EIRAU3 follow-up study 
in paper II, we could report severe fatigue (VAS > 40 mm) in 19% of the early RA patients at 
the 3-year follow-up, and 12% with sleep problems. The data on fatigue prevalence is in line 
with earlier reports in RA [80]. We have also investigated the potential connection between 
remaining pain and fatigue. In paper II, remaining pain one year after diagnosis strongly 
predict fatigue. In this paper, we use the definition of VAS fatigue, with >40 mm being 
suggestive of severe fatigue [162, 163]. Due to the registry approach, we were limited to this 
fatigue assessment only, and could not  investigate other potentially important aspects of 
fatigue. However, also sleep problems were predicted by remaining pain, supporting the 
general impact of pain on several aspects of fatigue.  In conclusion, our data is in line with 
several earlier studies that report strong relations between pain and fatigue in RA [82, 92, 164] , 
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and underscore the importance of early pain suppression to avoid severe fatigue later in the 
disease course. 
5.6 AUTONOMIC FUNCTION IN RA – RELATED TO CNS MECHANISMS  
Endogenous pain mechanisms are closely coupled to the autonomic nervous system, and a 
reduced vagal tone has been associated with generalized pain syndromes [165] . As mentioned, 
RA is also associated with a reduced vagal tone[99, 166], but the underlying mechanisms have 
not been fully elucidated. Furthermore, the reduced autonomic function in RA has not earlier 
been coupled to intrathecal cytokine levels or any neuromediator in human CNS. In paper IV 
we could confirm a reduced autonomic function, displayed by a decreased HF value in RA 
compared to controls. Moreover, the cholinergic anti-inflammatory pathway comprise an 
important neuroregulatory mechanism, acting through the vagus nerve, and regulating 
systemic inflammation. In the CNS, the vagus nerve function is regulated by action of 
muscarinic receptors [167] , and interestingly, earlier studies have shown that IL-1 may cause 
dysfunction in cholinergic neurotransmission [168] . Notably, our data in paper IV display that 
RA intrathecal levels of  IL-1β was markedly higher than serum levels (figure 12), suggesting 
local production in the CNS of this cytokine. Actually, IL-1β was the only CSF cytokine 
having this pattern, and IL-6 and other cytokines instead displayed higher serum than CSF 
levels (figure 12). These results strengthen the hypothesis that the cell source of the increased 
IL-1β production may be resident cells, for example glia cells in the CNS. Moreover, CSF IL-
1β levels were significantly correlated to reduced parasympathetic activity in the RA patients. 
Based on our data, we may then propose a possible mechanistic model on the involvement of 
intrathecal IL-1β in parasympathetic regulation: The systemic inflammation in RA leads to 
activation of afferent vagus, and signaling to the vagus nuclei of the brain stem. However, 
high IL-1β levels (as a result of systemic inflammation) leading to an activated state of 
resident cells of the CNS [70] will hamper the efferent vagus regulation, through negative 
action on muscarinic receptors in the brain stem. These mechanisms will result in a 
dysfunctional autonomic regulation through the inflammatory reflex, and further insufficient 
control of systemic and peripheral inflammation in the disease (figure 13). The coupling 
between systemic inflammation and autonomic dysfunction is also supported by a recent 
study by Koopman et al, showing that reduced autonomic activity is found also in arthritis 
patients at risk of developing RA [103]. The potential action of intrathecal cytokines on 
autonomic regulation is further supported by the finding that the anti-inflammatory cytokine 
IL-10 was inversely correlated to LF,  and serum IL-6, but not CSF IL-6, was also correlated 
to reduced autonomic activity. Moreover, in FM patients, we could not find any significant 
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correlations between intrathecal cytokines and autonomic function, which is in line with the 
fact that the autonomic balance in FM is not likely to be regulated by central nervous immune 
activation, but rather by pain regulation, as indicated by the increased sympathetic activity 
compared to controls and RA (paper IV), which is also in line with earlier reports[105, 169]. In 
conclusion, reduced vagal function in RA may be related both to the increased systemic 
inflammation that is a feature of the disease, but also to central nervous immune activation. 
These findings may be important for further investigations of the inflammatory reflex in the 
human setting, and also concerning the development of interventions based on cholinergic 
immune regulation .   
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Figure 12. Comparison of CSF and serum IL-6 and IL-1beta in RA 
patients. 
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Figure 13. The cholinergic antiinflammatory pathway, with a model for 
central nervous impact on autonomic regulation in RA (marked in red). 
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6 CONCLUDING REMARKS  
Pain affects all RA patients at diagnosis, and is the major symptom bringing the patient to the 
rheumatologist for the first time. Several earlier reports have shown that a significant part of 
patients continue to have pain during the RA course, and that inflammatory remission is not 
automatically associated with pain relief. Moreover, RA is associated with an increased risk 
for the development of complicating pain conditions, known as widespread pain, that may 
further impair function and work ability.  
In order to initiate preventive strategies for development of WSP in early RA, it is vital to 
map the pain problem and the predictive factors for development of WSP. Moreover, there is 
a need for epidemiological tools, i.e. useful pain outcomes in the defining of pain patterns in 
early RA. This thesis have aimed to investigate pain patterns in RA with a special focus on 
the discrepancy between pain in the individual patient on one hand, and objective measures of 
inflammation on the other. This work has resulted both in the definition of potentially 
clinically useful pain outcomes as well as the identification of the strongest clinical predictors 
in this context. Moreover, we have also investigated biological central nervous mechanisms 
that differ RA pain from dysfunctional pain conditions, such as fibromyalgia.   
We show that significant remaining pain after first-line antirheumatic treatment is quite 
common in early RA, and also affects a third of patients with good clinical response to the 
drug. This is interesting, and warrants further observational studies with this pain outcome of 
other antirehumatic treatments both in early and established RA.  
We have also defined a registry-based index for WSP, that has later been validated against 
SF36. This tool may prove important in further observational studies, and subsequent studies 
on prediction for work ability and sickness leave are ongoing. In addition, our work has also 
pointed out that development of WSP in RA is not uncommon, and may contribute 
significantly to decreased quality of life and reduced work capacity. 
The aiming for control of inflammation is now a natural hallmark in the treatment strategies 
for rheumatoid arthritis (RA). However, whereas rheumatologists in general have put more 
focus into achieve complete inflammation control of the disease, several patient-reported data 
indicate that although the inflammation is well-treated, other symptoms such as pain and 
fatigue have a substantial impact on the patient with RA. Data from this thesis also show 
clearly that the development of stable pain conditions occur mostly the first years after 
diagnosis of RA. When pain conditions manifest, such as WSP, these are not further 
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improved with immune suppressive drugs, and there is a lack of efficient pharmacological 
treatments for WSP. However, if patients at risk for development of pain conditions can be 
identified early in the disease, this could increase the possibilies to prevent further WSP 
development.  
Hopefully, the next step in rheumatology treatment strategies and guidelines could be aiming 
also for pain remission in the disease. This could be accomplished through I) early 
identification of patients at risk of developing pain conditions in connection to RA II) 
efficient immune suppressive treatment to further suppress inflammation to a minimum, and 
III) individual non-pharmacological and pharmacological intervention strategies of pain early 
in the disease.  
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